目的观察不同病理类型及分期的子宫内膜癌患者和健康对照组的血清中催乳素(prolactin)水平及CA125水平的变化,旨在探讨催乳素与子宫内膜癌不同病理分期类型之间的关系。方法选取潍坊市益都中心医院妇科因子宫内膜癌入院,经手术治疗并确诊的子宫内膜癌患者37例,根据不同手术-病理分期标准分组。抽取各组患者和正常对照组外周静脉血5ml,应用微粒子酶免分析法(microparticle enzyme immunoassay,MEIA)检测PRL及CA125水平,观察各组间PRL及CA125水平的表达情况。结果子宫内膜癌患者PRL及CA125水平较正常对照组明显增高(P均<0.05),且高催乳素血症发生率明显高于高CA125血症(P均<0.01)。结论对子宫内膜癌患者,PRL可以作为较CA125更好的肿瘤标志物。 Objective To observe the serum levels of prolactin and CA125 in endometrial carcinoma patients with different pathological types and stages, and to analyze the relationship between prolactin and different pathological stages of endometrial carcinoma . Methods 37 patients with endometrial cancer who underwent gynecological endometrial cancer admitted to Yidu Central Hospital of Weifang City were enrolled in this study. Thirty-seven patients with endometrial cancer who underwent surgical treatment and were diagnosed were divided into groups according to different surgical-pathological staging criteria. Peripheral venous blood 5 ml was collected from each group of patients and normal control group. The levels of PRL and CA125 were detected by microparticle enzyme immunoassay (MEIA). The expression of PRL and CA125 in each group were observed. Results The levels of PRL and CA125 in patients with endometrial cancer were significantly higher than those in normal controls (all P <0.05), and the incidence of hyperprolactinemia was significantly higher than that of patients with high CA125 (all P <0.01). Conclusion In patients with endometrial cancer, PRL can be a better tumor marker than CA125.